Standing Order
All companies

Biotech

Regeneron Pharmaceuticals, Inc.

REGNNASDAQdiversified
Market cap$94B
Conviction4/ 5
HQTarrytown, NY
View full dashboard

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Price · 1Y

$920.69

+87.6%

Thesis

Regeneron pairs a durable, cash-generative Eylea retinal franchise with a fast-growing Dupixent business co-developed with Sanofi across atopic and inflammatory indications. The pipeline extends into oncology (Libtayo and bispecifics) and obesity-adjacent metabolic assets.

The franchise has the rare combination of high quality earnings and an active, internally discovered pipeline — biosimilar pressure on Eylea is the main overhang, with Eylea HD partly mitigating it.

Catalysts

  • Eylea HD share gains slowing biosimilar erosion
  • Dupixent indication expansions (COPD and beyond)
  • Oncology readouts across the bispecific antibody pipeline
  • Capital deployment given the strong cash position

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Oct 30
    Financial resultsSEC

    8-K filing (items 2.02, 9.01) disclosing financial results and exhibits.

  • Oct 6
    OtherSEC

    8-K filing with items 1.01 (material agreement), 2.02 (financial condition), and 8.01 (other events).

  • Sep 30
    LeadershipSEC

    8-K filing with items 5.02 and 9.01 disclosing officer departure or appointment.

  • Jul 30
    Financial resultsSEC

    8-K filed with items 2.02 and 9.01 disclosing financial results.

  • Jul 6
    Financial resultsSEC

    Regeneron filed Form 8-K item 2.02 on results of operations and financial condition.

Not financial advice — research and opinion only. Disclosures